425: Curaleaf Fact Sheet Counters Aurora's Claims on Acquisition

Curaleaf Holdings issues a fact sheet to refute Aurora Cannabis's statements regarding its acquisition proposal, emphasizing Curaleaf's superior offer and financial performance.

Summary

• Curaleaf Holdings has released a fact sheet to address what it perceives as misleading statements from Aurora Cannabis concerning Curaleaf's proposal to acquire Aurora.
• The fact sheet aims to provide shareholders with factual information to evaluate Curaleaf's offer against Aurora's standalone plan.
• Curaleaf asserts its offer represents a significant premium, highlighting a 45% premium overall and a 110% premium when excluding cash on Aurora's balance sheet.
• The company contrasts its positive operating cash flow of $447 million since FY21 with Aurora's negative operating cash flow of over C$480 million since FY21.
• Curaleaf refutes claims of its shares being overvalued, citing Aurora's own advisor and Curaleaf's leadership in profitability and cash flow generation.
• The filing addresses concerns about Curaleaf's leverage, stating its profitability and cash flows support its debt, unlike Aurora's dilutive equity issuances.
• Curaleaf claims Aurora never discussed price or entered into a confidentiality agreement, despite Aurora's assertions of substantive discussions.
• The company defends the $5.00 cap on its offer, noting it represents a significant premium and that Aurora's board could adjust the bid period.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, as Curaleaf is actively defending its acquisition proposal and highlighting its strengths against Aurora Cannabis's criticisms, indicating a strong conviction in its offer.

Positives

• Curaleaf's offer includes a 45% premium, which is noted as one of the higher premiums in Canadian M&A over the past decade.
• Excluding cash on Aurora's balance sheet, Curaleaf's offer represents a 110% premium.
• Curaleaf generated $447 million in positive operating cash flow since FY21, contrasting with Aurora's negative operating cash flow.
• Curaleaf is positioned as the largest publicly traded cannabis company globally, leading in profitability and cash flow generation.
• Curaleaf's balance sheet is presented as favorable compared to peers, with profitability and cash flows supporting its debt.
• Curaleaf's offer includes approximately 19% cash consideration, aligning with precedent Canadian cannabis M&A transactions.
• Curaleaf's U.S. market exposure is framed as an advantage, representing the world's largest cannabis market.
• Curaleaf's management has significant personal investment in the company, with insiders holding nearly US$500 million.

Negatives

• Aurora has been issuing shares through its At-the-Market (ATM) program at prices materially below the value implied by Curaleaf's offer.
• Aurora's standalone plan has resulted in approximately C$5 billion of impairments and C$130 million of business transformation costs over nearly six years.
• Aurora has overseen negative operating cash flow exceeding C$480 million since FY21.
• Aurora's CEO, Miguel Martin, has overseen a 97% share decline.
• Aurora's management guidance suggests fiscal 2027 revenue is expected to decline to fiscal 2025 levels, with adjusted EBITDA lower than the prior year.
• Aurora has raised over US$400 million since September 2020 through equity issuances, diluting existing shareholders.
• Aurora's board rejected Curaleaf's proposal without discussing price or entering into a confidentiality agreement.
• Aurora insiders hold approximately 10% of the transaction value payable in the event of a change in control.

Risks

• Aurora's continued use of its ATM program at prices below the implied offer value dilutes existing shareholders.
• Aurora's standalone plan has a history of significant impairments and business transformation costs.
• Aurora's management guidance indicates deteriorating future financial performance.
• Curaleaf's leverage is presented as a potential risk to future equity holders, though Curaleaf counters this by highlighting its cash flow generation.
• The $5.00 cap on Curaleaf's offer is a point of contention, potentially limiting upside for Aurora shareholders.
• Aurora shareholders may be concerned about receiving a minority stake in a company with multi-voting shares, though Curaleaf argues this is standard for large companies.
• The transaction may not be tax efficient for U.S. shareholders, although Curaleaf suggests negotiation on tax structuring.
• Curaleaf's U.S. business operates in a federally illegal market, though Curaleaf views this exposure as an advantage.

Future Outlook

Aurora's management guidance projects a decline in fiscal 2027 revenue to fiscal 2025 levels and lower adjusted EBITDA compared to the prior year. Curaleaf, conversely, highlights its strong cash flow generation and potential benefits from U.S. federal reform, including lower taxes, improved free cash flow, and broader institutional ownership.

Management Comments

• "Curaleaf believes shareholders deserve the facts."
• "While Aurora has focused on criticizing Curaleaf's proposal, shareholders should focus on the fundamental question: which company has a clearer vision for the future and a stronger record of creating shareholder value?"
• "Aurora is asking shareholders to continue supporting a 'turnaround' strategy that has had nearly six years to prove itself."
• "Aurora can't have it both ways: if Curaleaf's valuation is too high, why is it not high enough for Aurora?"
• "If the cap is the issue, the Board can fix it."
• "Federal reform is not a one-time event. The value creation comes from what follows: immediately, materially lower cash taxes and improved free cash flow, and potentially broader institutional ownership, lower financing costs, greater M&A flexibility, access to credit cards, and uplisting to a major U.S. exchange."
• "Our U.S. medical business represents approximately 60%. What's more, U.S. cannabis regulation has been moving steadily in one direction: toward greater normalization, broader acceptance and reduced regulatory barriers."

Industry Context

StockSavvy.ai notes this filing is a critical engagement in the ongoing battle for the acquisition of Aurora Cannabis. Curaleaf is leveraging its position as a larger, more profitable entity to persuade Aurora's shareholders that its offer is superior to Aurora's standalone strategy, which has faced significant financial challenges and underperformance.

Comparison to Industry Standards

• Curaleaf's offer premium of 45% is cited as among the higher Canadian M&A premiums of the past decade.
• Curaleaf's positive operating cash flow of $447 million since FY21 is contrasted with Aurora's negative operating cash flow of over C$480 million in the same period.
• Curaleaf highlights its leadership in profitability and cash flow generation among cannabis companies.
• The cash consideration of approximately 19% in Curaleaf's offer is stated to be in line with precedent Canadian cannabis M&A transactions.
• Curaleaf points to multi-class voting structures used by major companies like Alphabet, Meta, Shopify, and Palantir, as well as cannabis peers Green Thumb and Trulieve, to justify its own structure.

Corporate Governance

Stakeholder Impact

• Shareholders: The filing directly addresses shareholders of both Curaleaf and Aurora, aiming to influence their decision regarding the acquisition proposal by highlighting perceived value differences and factual inaccuracies.
• Aurora Shareholders: Are presented with arguments that Curaleaf's offer provides a significant premium and better future value compared to Aurora's standalone plan, which has historically underperformed.
• Curaleaf Shareholders: Are reassured about the company's financial health, profitability, and strategic advantages, particularly its U.S. market exposure and potential benefits from federal reform.

Next Steps

• Shareholders are encouraged to review the fact sheet at grow.curaleaf.com to evaluate Curaleaf's offer.
• Curaleaf suggests that if Aurora's Board is concerned about the offer cap, they can shorten the bid period to 35 days and engage constructively.
• Curaleaf expects to trade on a major U.S. exchange once the U.S. federal rescheduling process is completed.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' for Curaleaf shareholders. While the company is actively defending its acquisition proposal and highlighting its strengths, the outcome of the acquisition remains uncertain. The filing provides a strong defense of Curaleaf's offer and financial position relative to Aurora, but the ultimate success of the acquisition and its impact on Curaleaf's stock price depend on Aurora's response and shareholder decisions.

Keywords

acquisition, cannabis, merger, takeover, shareholder value, financial performance, operating cash flow, premium offer